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Background: Second-generation everolimus-eluting stents (EES) have demonstrated superiority over first-generation drug-eluting stents (DES) for 
single vessel disease. This study aimed to compare the safety and efficacy of EES to first-generation DES in multivessel disease (MVD).
methods: A cohort of 1,285 patients (3124 lesions) with ≥2 diseased vessels were treated with either FGS (n=1,002) or EES (n=283). The rates 
of death, myocardial infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), definite stent thrombosis, and major 
adverse cardiac events (MACE; defined as the combined incidence of TVR, death and non-fatal MI) were compared at 1 year.
results: Baseline characteristics were mostly matched (Table) expect for lower left ventricular ejection fraction and lower incidence of stable 
angina in the FGS group (p=0.001 and 0.013, respectively). At 1 year, MACE rate was lower in the EES group (9.5 vs. 15.7%, p=0.01). Multivariable 
analysis demonstrated that the use of EES predicted a higher chance of freedom of MACE at 1 year (HR 0.58 (0.38-0.87), p=0.009, 95%CI) with 
similar results after adjusting for days of clopidogrel adherence.
conclusion: The use of EES in patients with MVD is both safer and more effective compared to first-generation DES. This should encourage the use 
of EES in MVD and prompt future comparisons of second-generation DES to coronary artery bypass grafting surgery in this subset of patients. 
Table: Baseline Characteristics and Clinical Outcome
Variable FGS (n=1002) EES (n=283) p value
Baseline Demographic and Clinical Characteristics
Age 65.33±11.92 65.72±11.20 0.615
Men 664 (66.3%) 184 (65.2%) 0.75
Insulin-dependent diabetes mellitus 100 (10.1%) 35 (12.4%) 0.266
Hypertension 867 (86.5%) 256 (9.5%) 0.078
Ejection fraction (%) 0.48±0.14 0.51±0.11 0.001
Stable angina 297 (29.7%) 106 (37.5%) 0.013
Number of diseased vessels 2.41±0.60 2.28±0.48 <0.001
Number of implanted stents per patient 2.45±0.91 2.47±0.93 0.77
Taxus stent 35.2% 0
Cypher stent 64.8% 0
Clinical Safety and Efficacy at 1 year
Death 73 (7.3%) 5 (1.8%) <0.001
Myocardial infarction (MI) 17 (1.7%) 5 (1.8%) 0.798
Target lesion revascularization (TLR) 65 (6.5%) 18 (6.4%) 0.866
Target vessel revascularization (TVR) 90 (9.3%) 23 (8.2%) 0.584
Stent thrombosis 14 (1.4%) 0 0.049
MACE (composite of death, MI & TVR) 157 (15.7%) 27 (9.5%) 0.01
